Oral Penem Approval Forces AMR Supply Chain Reckoning

Iterum Therapeutics US Limited now holds FDA approval for ORLYNVAH (sulopenem etzadroxil and probenecid), an oral tablet combination indicated for uncomplicated urinary tract infections (uUTI) in adult female patients with limited or no alternative oral antibiotic options. Approved on October 25, 2024, the product introduces a penem-class antibiotic in oral solid dosage form, a configuration that carries distinct API sourcing, formulation stability, and process validation demands that manufacturers and CDMOs will need to address as AMR-driven demand for reserve antibiotics intensifies.

ORLYNVAH pairs sulopenem etzadroxil, a penem antibiotic prodrug, with probenecid, a renal transport inhibitor included to sustain therapeutic drug exposure. The approved regimen is 500 mg sulopenem etzadroxil and 500 mg probenecid, administered orally twice daily for five days. The fixed-dose combination tablet format raises immediate questions around blend uniformity, moisture sensitivity of the penem moiety, and the GMP controls required to maintain consistent potency across commercial batches under 21 CFR Part 211.

FDA based its approval on evidence from two randomized, double-blind clinical trials enrolling 3,861 adult females with uUTI across 246 sites in the United States, Russia, and Ukraine. The efficacy population was defined as patients presenting with urinary symptoms and a confirmed positive urine culture. In Trial 1, 2,214 patients received either ORLYNVAH or oral amoxicillin/clavulanate 875 mg/125 mg twice daily for five days. The indication is specifically scoped to uUTI caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, and is restricted to patients for whom alternative oral options are limited or unavailable, a positioning that places ORLYNVAH firmly within stewardship-sensitive prescribing frameworks.

For QA and regulatory affairs teams, the dual-active tablet format will require robust process validation strategies addressing the physicochemical compatibility of the two APIs, alongside ICH Q10-aligned pharmaceutical quality system documentation to support commercial scale-up. The trial's geographic enrollment spread, with 700 patients from Russia and Ukraine, may also prompt additional scrutiny during post-approval inspections regarding data integrity and site compliance standards. Source: FDA Drug Trials Snapshots, ORLYNVAH, published April 29, 2026.